Safety of MR liver specific contrast media
| Autor: | Judith A. W. Webb, Henrik S. Thomsen, Marie-France Bellin, Aart J. van der Molen, Sameh K. Morcos |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Biliary Tract Diseases Iron Contrast Media Gadolinium Humans Medicine Radiology Nuclear Medicine and imaging Medical physics Magnetite Nanoparticles GADOBENATE DIMEGLUMINE Neuroradiology Manganese medicine.diagnostic_test business.industry Liver Diseases Dextrans Oxides Magnetic resonance imaging Interventional radiology General Medicine Magnetic Resonance Imaging Ferrosoferric Oxide Clinical trial Liver Radiology business Superparamagnetic iron oxide |
| Zdroj: | European Radiology. 15:1607-1614 |
| ISSN: | 1432-1084 0938-7994 |
| DOI: | 10.1007/s00330-004-2612-x |
| Popis: | Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink